QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China
QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.
How this was made

The 30-second read
Why it matters
The guidance cut and China revenue drop are likely to depress the stock in the short term, though the announced cost‑saving program may mitigate longer‑term risk.
Market read
The earnings miss and guidance reduction are material for QDEL and may influence sentiment across the diagnostic sector.
What to watch
The $80M annual savings program and restructuring charges may improve cash flow in 2027.
Background
QuidelOrtho delivered its Q3 2026 earnings call, highlighting a revenue decline and revised guidance.
Ticker impact
QDEL reported Q3 revenue down 12% to $619M and cut full-year revenue guidance to $2.52‑$2.54B.
likely pressure as the market prices in lower revenue and guidance.
Guidance reduction and weak China sales are material; cost‑saving program will not offset until 2027.
Market effects
Diagnostic and IVD sector faces pricing pressure in China, potentially weighing peers.
US healthcare stocks may see modest pullback as investors reassess China exposure.
Signals broader concerns for global IVD manufacturers with China exposure.
Counterpoint
If China pricing stabilizes later, the cost‑saving program could boost margins and drive upside.
Key entities
- CEOBrian Blaser
Provided commentary on operating model changes and China outlook.
- CFOMicah Young
Outlined the $80M savings program and leverage metrics.


